Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

BACKGROUND: Moxetumomab pasudotox is a recombinant CD22-targeting immunotoxin. Here, we present the long-term follow-up analysis of the pivotal, multicenter, open-label trial (NCT01829711) of moxetumomab pasudotox in patients with relapsed/refractory (R/R) hairy cell leukemia (HCL). METHODS: Eligibl...

Descripción completa

Detalles Bibliográficos
Autores principales: Kreitman, Robert J., Dearden, Claire, Zinzani, Pier Luigi, Delgado, Julio, Robak, Tadeusz, le Coutre, Philipp D., Gjertsen, Bjørn T., Troussard, Xavier, Roboz, Gail J., Karlin, Lionel, Gladstone, Douglas E., Kuptsova-Clarkson, Nataliya, Liu, Shiyao, Patel, Priti, Rotolo, Federico, Mitry, Emmanuel, Pastan, Ira, Giles, Francis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905554/
https://www.ncbi.nlm.nih.gov/pubmed/33627164
http://dx.doi.org/10.1186/s13045-020-01004-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905554/
https://www.ncbi.nlm.nih.gov/pubmed/33627164
http://dx.doi.org/10.1186/s13045-020-01004-y

Ejemplares similares